- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
IVI Research Brief Uses Insurance Value to Determine Long-Term Value of Therapies
A research brief from the Innovation and Value Initiative (IVI) looked at how the concept of insurance value can help stakeholders understand the value of therapies to the broader population.
A research brief from the Innovation and Value Initiative (IVI) looked at how the concept of insurance value can help stakeholders understand the value of therapies to the broader population. Insurance value measures the value that medical technologies offer healthy individuals by reducing the physical risks of possible illness, and the concept has been suggested as one of several elements to improve and enhance conventional cost-effecteness analysis.
The brief used IVI's Open-Source Value Platform mofel for rheumatoid arthritis (RA) to explore the application of insurance value because treatent of RA focuses on reducing impacts on quality of life rather than addressing mortality concerns.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Stagnation in Reimbursement Keeps Biomedical Innovation From Reaching All Patients, COA Panel Says
September 9th 2025Panelists at the Community Oncology Alliance Payer Exchange Summit discuss the urgent need for innovative reimbursement models in cancer care to match advancements in biomedical technology and drug discovery.
Read More
